Carestream Dental vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Digital dental imaging and practice management software provider offering intraoral sensors, 3D imaging systems, and clinical software for dental practices and institutions worldwide.
About
Carestream Dental is a Rochester, New York-based provider of dental imaging technology and practice management software, operating as a business unit spun off from Carestream Health. The company offers a comprehensive portfolio of dental imaging solutions spanning intraoral X-ray sensors, panoramic imaging systems, 3D cone beam CT (CBCT) scanners, and the clinical software required to acquire, store, manage, and interpret dental images. Carestream Dental serves general dental practices, specialty clinics, dental schools, and group dental organizations globally.\n\nThe company's imaging software platforms, including CS Imaging and CS PracticeWorks, integrate clinical image management with practice workflow features such as patient scheduling, charting, and treatment planning. This integration between imaging hardware and software creates a vertically integrated ecosystem that encourages multi-product adoption within a single practice. Carestream Dental has built a significant installed base in North America and Europe over several decades of operation as part of larger parent organizations including Kodak and Carestream Health.\n\nCarestream Dental competes in the dental technology market against companies such as Dentsply Sirona, Planmeca, and Patterson Companies. The transition from film-based to digital radiography was a key growth driver historically, and the company now focuses on 3D imaging adoption, digital impression workflow integration, and cloud-connected imaging tools. Its deep roots in imaging hardware combined with proprietary software give it a bundled solution advantage when selling into practices upgrading their full radiography infrastructure.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.